Benjamin Halladay was named Chief Financial Officer of Achieve Life Sciences, Inc., effective October 5, 2026. As of November 6, 2026, Achieve Life Sciences, Inc. has reported 4 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 16, 2026 to October 1, 2026, naming 2 appointments and 2 departures (Form 8-K, October 1, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Achieve Life Sciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Benjamin Halladay · Role: Chief Financial Officer · Effective: 2026-10-05 · 8-K, 2026-10-01
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-06-02
- · In / out: Out · Person: Thomas King · Effective: 2026-06-08 · 8-K, 2026-05-12
- · In / out: Out · Person: Richard Stewart · Role: Chief Executive Officer · Effective: 2026-04-18 · 8-K, 2026-04-16
Achieve Life Sciences, Inc. reported changes in 4 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-16 to 2026-10-01. They name 4 people, with 2 appointments and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Achieve Life Sciences, Inc. files it.
Also on the record for Achieve Life Sciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 17, 2026 | Stake report, Schedule 13G, by Logos Global Management LP | 9.99% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G, by JANUS HENDERSON GROUP Ltd. | 5.4% of the class | 5%+ stakes | Source |
| July 28, 2026 | Stake report, Schedule 13G/A, by Franklin Resources, Inc. | 8.3% of the class | 5%+ stakes | Source |
| July 27, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.1% of the class | 5%+ stakes | Source |
| July 8, 2026 | Stake report, Schedule 13G, by Vivo Opportunity, LLC | 5% of the class | 5%+ stakes | Source |
| May 7, 2026 | Stake report, Schedule 13G/A, by Franklin Resources, Inc. | 6.2% of the class | 5%+ stakes | Source |
| April 27, 2026 | Stake report, Schedule 13D, by venBio Global Strategic Fund V, L.P. | 9.99% of the class | 5%+ stakes | Source |
| April 24, 2026 | Stake report, Schedule 13D, by TPG GP A, LLC | 12.6% of the class | 5%+ stakes | Source |
| April 24, 2026 | Stake report, Schedule 13G, by Frazier Life Sciences Public Fund, L.P. | 6.5% of the class | 5%+ stakes | Source |
| April 24, 2026 | Stake report, Schedule 13G, by Paradigm BioCapital Advisors LP | 9.2% of the class | 5%+ stakes | Source |
| April 24, 2026 | Stake report, Schedule 13G, by Venrock Healthcare Capital Partners III, L.P. | 5.2% of the class | 5%+ stakes | Source |
| January 29, 2026 | Stake report, Schedule 13G/A, by Franklin Resources, Inc. | 11.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Achieve Life Sciences, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Achieve Life Sciences, Inc. and the records around it.
Achieve Life Sciences, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- venBio Global Strategic Fund V, L.P. also filed stake reports on 1 other company: Yarrow Bioscience, Inc. (Aug 2026)
- Logos Global Management LP also filed stake reports on 14 other companies: Longeveron Inc. (Sep 2026), Yarrow Bioscience, Inc. (Aug 2026), Avalo Therapeutics, Inc. (May 2026)
- TPG GP A, LLC also filed stake reports on 15 other companies: Allogene Therapeutics, Inc. (Sep 2026), TPG Inc. (Aug 2026), Ceribell, Inc. (Aug 2026)
Watch Achieve Life Sciences, Inc.
Get an email when Achieve Life Sciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Achieve Life Sciences, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Achieve Life Sciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Achieve Life Sciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 17 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-01 | In | Chief Financial Officer | 2026-10-05 | 8-K, 2026-10-01 | |
| 2026-06-02 | Reported | not named in the filing | 8-K, 2026-06-02 | ||
| 2026-05-12 | Out | 2026-06-08 | 8-K, 2026-05-12 | ||
| 2026-04-16 | Out | Chief Executive Officer | 2026-04-18 | 8-K, 2026-04-16 | |
| 2026-04-16 | In | Chief Executive Officer | 2026-04-18 | 8-K, 2026-04-16 |
Who leads Achieve Life Sciences, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Benjamin Halladay, appointed, effective 2026-10-05 (filed 2026-10-01).
- Chief Executive Officer: Richard Stewart, departure reported, effective 2026-04-18 (filed 2026-04-16). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Achieve Life Sciences, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Achieve Life Sciences, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Achieve Life Sciences, Inc.Every change, in the filing's words
Appointed: Benjamin Halladay, Chief Financial Officer, effective 2026-10-05
On October 1, 2026, Achieve Life Sciences, Inc. (the " Company ") announced that the Board of Directors of the Company (the " Board ") appointed Benjamin Halladay as the Company's Chief Financial Officer and "principal financial officer," effective as of October 5, 2026 (the " Appointment Date ").
- Before joining the Company, Mr. Halladay, age 40, served in several different roles at Esperion Therapeutics, Inc., a pharmaceutical company, including as Chief Financial Officer from November 2022 until September 2026, as Senior Director of Finance from August 2022 until November 2022, as Director of Financial Planning and Analysis from July 2021 until August 2022, and as Finance Manager of Tech Operations from January 2020 until July 2021.
- From May 2017 through January 2020, Mr. Halladay served as Global Finance Manager of NOV Inc. (formerly National Oilwell Varco, Inc.), an oilfield services and equipment trading company.
- Mr. Halladay received his Bachelor's degree in Business Administration - History from Syracuse University, his Master's degree in Business Administration - Finance and Accounting from Fordham Gabelli School of Business, and is a Certified Public Accountant.
- The conclusion of Mr. Oki's employment is not a result of any disagreement regarding the Company's financial statements or disclosures.
Reported
On May 29, 2026, the Board of Directors (the "Board") of Achieve Life Sciences, Inc. (the "Company") appointed Jeff Farrow and Reid Waldman, M.D.
- Mr. Marrow has also been appointed to the Nominating and Governance Committee of the Board as a member and to the Audit Committee of the Board as its Chair.
- Dr. Waldman has also been appointed to the Commercial Committee of the Board as a member and to the Compensation Committee of the Board as its Chair.
- The Incoming Directors' compensation will be as provided under the Company's non-employee director compensation program (the "Non-Employee Director Compensation Program").
- In connection with their appointments as non-employee directors of the Board and consistent with the Non-Employee Director Compensation Program, the Incoming Directors will each be entitled to receive a pro-rated $40,000 annual retainer for service as a non-employee director for the Company's fiscal year ending December 31, 2026, as well as additional cash compensation for service on the Board committees.
- In addition, consistent with the Non-Employee Director Compensation Program, the Incoming Directors will each receive a stock option to purchase 47,250 shares of the Company's common stock, which will vest monthly over three years, subject to continued service to the Company.
Departing: Thomas King, effective 2026-06-08
On May 7, 2026, Thomas King informed the Board that he has elected to resign from his position as a member and as chairman of the Board, effective as of June 8, 2026.
- Appointment of Board Member In connection with the previously reported private placement (the "Private Placement") of the Company's securities, and pursuant to the designation right granted to Frazier Life Sciences, on May 11, 2026, the Company's board of directors (the "Board") appointed Christopher Martin to serve as a director of the Company, effective immediately.
- Mr. Martin's compensation will be as provided under the Company's non-employee director compensation program (the "Non-Employee Director Compensation Program").
- In connection with his appointment as a non-employee director of the Board and consistent with the Non-Employee Director Compensation Program, Mr. Martin will be entitled to receive a pro-rated $40,000 annual retainer for service as a non-employee director for the Company's fiscal year ending December 31, 2026.
- In addition, consistent with the Non-Employee Director Compensation Program, Mr. Martin will receive a stock option to purchase 47,250 shares of the Company's common stock, par value $0.001 per share ("Common Stock"), which will vest monthly over three years, subject to continued service as a director on the Board or employee or consultant of the Company.
Departing: Richard Stewart, Chief Executive Officer, effective 2026-04-18
Departure of Chief Executive Officer In connection with the Private Placement, on April 15, 2026, Richard Stewart, the Company's Chief Executive Officer and a director, informed the Company's Board of Directors (the "Board") of his intention to step down from his position as the Company's Chief Executive Officer, President and "principal executive officer," effective as of April 18, 2026 (the "Separation Date").
Appointed: Andrew Goldberg, Chief Executive Officer, effective 2026-04-18
Effective as of April 18, 2026 (the "Appointment Date"), the Company also announced that the Board appointed Andrew Goldberg as the Company's Chief Executive Officer, President and "principal executive officer." Dr. Goldberg was also appointed to the Board, effective as of the Appointment Date.
- Mr. Stewart will remain in his position as a member of the Board.
- Dr. Goldberg has served as a Portfolio Manager at Marshall Wace North America L.P., an alternative asset manager, since February 2024 and served as Managing Director from March 2021 until February 2024.
- Dr. Goldberg has served as a member of the Board of Tarsus Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, since August 2020 and Inquis Medical, Inc., a privately-held medical device company, since February 2024.
- Prior to Dr. Goldberg's role at Marshall Wace, Dr. Goldberg served as a principal and subsequently partner at Vivo Capital, a global healthcare investment firm that focuses exclusively on the life sciences industry, from February 2016 to March 2021.
- Prior to this, Dr. Goldberg was a consultant at McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies across a range of strategy, M&A, sales, marketing, and product development topics.
- Dr. Goldberg has also served as a board director or observer at numerous life sciences companies, including Veradermics Inc., Arcutis Biotherapeutics, Inc., Harmony Biosciences, Elektrofi, Parse Biosciences, and Forge Biologics.
- Dr. Goldberg is a U.S. board-certified physician in both Critical Care Medicine and Emergency Medicine.
Tools for this story
Each opens in a new tab, filled in for Achieve Life Sciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.